{
    "root": "312dc8f1-61ed-c571-e063-6294a90a4959",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "LEVETIRACETAM",
    "value": "20250325",
    "ingredients": [
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "LEVETIRACETAM",
            "code": "44YRR34555"
        }
    ],
    "indications": "levetiracetam extended-release tablets indicated treatment partial-onset seizures patients 12 years age older .",
    "contraindications": "initiate treatment dose 1,000 mg daily ; increase 1,000 mg every 2 weeks maximum recommended dose 3,000 mg daily ( 2 ) full prescribing information patients impaired renal function ( 2.1 )",
    "warningsAndPrecautions": "levetiracetam extended-release 500 mg tablets , usp white , oval , biconvex film-coated extended-release tablets debossed `` hh `` one side “ 172 ” side . supplied ndc : 70518-4005-00 ndc : 70518-4005-01 packaging : 30 1 blister pack packaging : 30 1 bottle plastic store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "levetiracetam extended-release tablets contraindicated patients hypersensitivity levetiracetam . included anaphylaxis angioedema [ ( 5.4 ) ] .",
    "indications_original": "Levetiracetam extended-release tablets are indicated for the treatment of partial-onset seizures in patients 12 years of age and older.",
    "contraindications_original": "Initiate treatment with a dose of 1,000 mg once daily; increase by 1,000 mg every 2 weeks to a maximum recommended dose of 3,000 mg once daily ( 2 ) See full prescribing information for use in patients with impaired renal function ( 2.1 )",
    "warningsAndPrecautions_original": "Levetiracetam extended-release 500 mg tablets, USP are white, oval, biconvex film-coated extended-release tablets debossed with \"HH\" on one side and “172” on the other side. They are supplied in\n                  \n                  NDC: 70518-4005-00\n                  NDC: 70518-4005-01\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 30 in 1 BOTTLE PLASTIC \n                  \n                  \n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].\n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Levetiracetam extended-release\n \n  tablets are contraindicated in patients with a hypersensitivity to levetiracetam\n \n  .Reactions have included anaphylaxis and angioedema [\n \n  see Warnings and Precautions (\n  \n   5.4)\n \n  ]."
}